Why the study?
Is circulating NRG-1β associated with disease severity and adverse outcomes in patients with chronic heart failure?
Is circulating NRG-1β associated with disease severity and adverse outcomes in patients with chronic heart failure?
Answers are grounded in this paper and cite their sources.
Serum NRG-1β is identified as a novel biomarker associated with disease severity and adverse outcomes in chronic heart failure.
Circulating NRG-1beta is independently associated with heart failure severity and risk of death or cardiac transplantation. These findings support a role for NRG-1/ErbB signaling in human heart failure and identify serum NRG-1beta as a novel biomarker that may have clinical applications.
No takes yet. Share an insight, caveat, or question.
Ky et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: